Phase-I Study of the new B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 as Monotherapy or in Combination with Zanubrutinib (zanu) in Patients (pat) with B-Cell Malignancies: preliminary Data

被引：0
|
作者：
Stilgenbauer, S. [1 ]
Opat, S. [2 ,3 ]
Cheah, C. Y. [4 ,5 ,6 ,7 ]
Lasica, M. [8 ]
Verner, E. [9 ,10 ]
Browett, P. J. [11 ]
Chan, H. [12 ]
Soumerai, J. D. [13 ]
Gonzalez, Barca E. [14 ]
Hilger, J. [15 ]
Fang, Y. [16 ]
Simpson, D. [15 ]
Tam, C. S. [17 ,18 ,19 ]
机构：
[1] Univ Ulm, Ulm, Germany
[2] Monash Hlth, Clayton, Australia
[3] Monash Univ, Clayton, Australia
[4] Sir Charles Gairdner Hosp, Nedlands, Australia
[5] Pathwest Lab Med, Nedlands, Australia
[6] Univ Western Australia, Sch Med, Crawley, Australia
[7] Linear Clin Res, Nedlands, Australia
[8] St Vincents Hosp Melbourne, Fitzroy, Australia
[9] Concord Repatriat Gen Hosp, Concord, Australia
[10] Univ Sydney, Sydney, Australia
[11] Auckland City Hosp, Auckland, New Zealand
[12] North Shore Hosp, Auckland, New Zealand
[13] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[14] Univ Barcelona, Inst Catala Oncol Hosp, Barcelona, Spain
[15] BeiGene USA Inc, San Mateo, CA USA
[16] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[17] Peter MacCallum Canc Ctr, Melbourne, Australia
[18] Univ Melbourne, Parkville, Australia
[19] Royal Melbourne Hosp, Parkville, Australia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V91
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [1] A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data
    Soumerai, Jacob D.
    Opat, Stephen
    Cheah, Chan Y.
    Lasica, Masa
    Verner, Emma
    Browett, Peter J.
    Chan, Henry
    Barca, Eva Gonzalez
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S268
  • [2] A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data
    Cheah, Chan Y.
    Tam, Constantine S.
    Lasica, Masa
    Verner, Emma
    Browett, Peter J.
    Anderson, Mary Ann
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Opat, Stephen
    BLOOD, 2022, 140 : 2321 - 2323
  • [3] Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib
    Tam, Constantine S.
    Verner, Emma
    Lasica, Masa
    Arbelaez, Alejandro
    Browett, Peter J.
    Soumerai, Jacob D.
    Hilger, James
    Fang, Yiqian
    Huang, Jane
    Simpson, David
    Opat, Stephen
    Cheah, Chan Yoon Y.
    BLOOD, 2021, 138
  • [4] PRELIMINARY SAFETY AND EFFICACY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES TREATED WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 IN MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB
    Ghia, P.
    Tam, C.
    Verner, E.
    Lasica, M.
    Arbelaez, A.
    Browett, P.
    Soumerai, J.
    Hilger, J.
    Fang, Y.
    Huang, J.
    Simpson, D.
    Opat, S.
    Cheah, C.
    HAEMATOLOGICA, 2022, 107 : 33 - 34
  • [5] A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenstrom Macroglobulinemia (WM): Preliminary Data
    Soumerai, Jacob D.
    Lasica, Masa
    Opat, Stephen
    Cheah, Chan Y.
    Chan, Henry
    Verner, Emma
    Barca, Eva Gonzalez
    Tedeschi, Alessandra
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    BLOOD, 2022, 140 : 9325 - 9327
  • [6] BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with Zanubrutinib in CLL/SLL patients: Preliminary phase 1 data
    Kesavan, Murali
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 65 - 65
  • [7] Preliminary Safety and Efficacy Of BGB-11417, a Potent and Selective B-Cell Lymphoma 2 (BCL2) Inhibitor, in Patients (Pts) with Acute Myeloid Leukemia (AML)
    Shortt, Jake
    Platzbecker, Uwe
    Tan, Shuh Ying
    Cannell, Paul
    Ng, Teng Fong
    Fong, Chun Yew
    Ramanathan, Sundra
    Rajagopal, Rajeev
    Leitch, Sophie
    Gasiorowski, Robin
    Grove, Carolyn
    Lenton, Douglas
    Tan, Peter
    Dinardo, Courtney
    Ling, Ming Tat
    Cheng, Si
    Liu, Yuan
    Co, Melannie
    Chan, Wai Y.
    Simpson, David
    Wei, Andrew H.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 144 - 144
  • [8] A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data
    Li, Caixia
    Wei, Jia
    Zhou, Keshu
    Liu, Peng
    Huang, He
    Li, Fei
    Dong, Yujun
    Cai, Qingqing
    Yang, Shenmiao
    Zhang, Xinyou
    Zhou, Hui
    Zhang, Lu
    Shi, Zaixing
    Liang, Zhiyu
    Wu, Binghao
    Wu, Depei
    BLOOD, 2022, 140 : 6717 - 6718
  • [9] A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
    Li, Caixia
    Wei, Jia
    Zhou, Keshu
    Liu, Peng
    Huang, He
    Li, Fei
    Cai, Qingqing
    Dong, Yujun
    Yang, Shenmiao
    Zhou, Hui
    Zhang, Xinyou
    Zhang, Lu
    Shi, Zaixing
    Liang, Zhiyu
    Wu, Binghao
    Wu, Depei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with Zanubrutinib in non-Hodgkin lymphoma or Waldenstrom macroglobulinemia patients
    Patten, Piers
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 113 - 113
12345